Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.050
-0.450 (-30.00%)
At close: Mar 27, 2026, 4:00 PM EDT
0.9800
-0.0700 (-6.67%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Alzamend Neuro Market Cap
Alzamend Neuro has a market cap or net worth of $3.99 million as of March 27, 2026. Its market cap has decreased by -9.62% in one year.
Market Cap
3.99M
Enterprise Value
1.28M
1-Year Change
-9.62%
Ranking
Category
Stock Price
$1.05
Market Cap Chart
Since the IPO on June 15, 2021, Alzamend Neuro's market cap has decreased from $1.15B to $3.99M, a decrease of -99.65%. That is a compound annual growth rate of -69.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 26, 2026 | 5.71M | -17.51% |
| Dec 31, 2025 | 6.92M | 9.79% |
| Dec 31, 2024 | 6.30M | -0.56% |
| Dec 29, 2023 | 6.34M | -88.37% |
| Dec 30, 2022 | 54.47M | -67.73% |
| Dec 31, 2021 | 168.82M | -85.28% |
| Jun 15, 2021 | 1.15B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Akari Therapeutics, | 4.51M |
| VivoSim Labs | 4.22M |
| Genprex | 4.22M |
| Revelation Biosciences | 4.20M |
| Can-Fite BioPharma | 4.11M |
| Silexion Therapeutics | 4.10M |
| Biodexa Pharmaceuticals | 4.05M |
| Indaptus Therapeutics | 3.99M |